Positive Results Announced in Largest Pivotal Phase 3 Trial

A Phase 3 study of oral zoliflodacin met the primary endpoint when compared against the combination of injectable ceftriaxone and oral azithromycin, a current international standard of care.Positive top-line study results are a significant milestone in the development of a first-in-class antibiotic against drug-resi...

Related Keywords

Germany , Luxembourg , Belgium , Geneva , Genè , Switzerland , South Africa , United Kingdom , Waltham , Leicestershire , China , Japan , United States , Canada , Thailand , Netherlands , Monaco , Australia , Swiss , Canton , America , Grand Duchy Of Luxembourg , Manica Balasegaram , David Patti , Pavel Raifeld , Global Antibiotic Research Development Partnership , Leo Model Foundation , Corporate Communications , Wellcome , African Medical Research Council , Us National Institute Of Allergy , Entasis Therapeutics Inc , Public Health Agency Of Canada , Drug Administration , World Health Organization , Head Of Communications , European Union , Innoviva Inc , Nasdaq , Jolla Pharmaceutical Company , University Of Alabama , Entasis Therapeutics , Global Antibiotic Research , Development Partnership , Innoviva Specialty Therapeutics , Executive Director , Protocol Chair , Emeritus Professor , Lancet Infectious Diseases , Chief Executive Officer , Therapeutics Limited , North America , Grand Duchy , South African Medical Research Council , Leo Model , Infectious Diseases , Neglected Diseases , Public Health Agency , Wellcome Trust , Specialty Therapeutics , Specialty Therapeutic ,